Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -45

Boston Scientific stock faces negative outlook as leverage risk rises

Acquisition Business restructuring Financial outlook AI-generated analysis

πŸ“‰ S&P Global Ratings revised Boston Scientific's credit outlook to negative, citing continued pressure on its WATCHMAN and electrophysiology franchises.

πŸ“Š Revenue growth is forecast at 4.4% for 2026 and 9% for 2027, a significant deceleration from the mid-to-high-teens rates seen in 2024 and 2025.

⚠️ The WATCHMAN franchise accounts for 10% of revenue and faces headwinds from clinical trial data uncertainty and intensifying competition.

πŸ₯ The electrophysiology division, contributing 16% of sales, is weighed down by competition from Johnson & Johnson, Medtronic, and Abbott.

πŸ’° The planned $14.5 billion acquisition of Penumbra is expected to close in early 2027, driving adjusted leverage above 3.6 times.

πŸ›‘ S&P expects management to limit additional acquisitions and share repurchases while integrating the Penumbra transaction and reducing debt.

πŸ’Έ Boston Scientific has launched a restructuring program targeting $500 million in cost savings through 2029 to restore growth and lower leverage.

πŸ“ˆ A return to a stable credit outlook requires mid-single-digit growth in core franchises and leverage reduction below the 2.5-times downside trigger.

πŸ’Ά Boston Scientific stock traded at 39.40 euros on November 10, 2026, reflecting concerns over execution risk and financing costs.

Bullish Signals
  • The acquisition of Penumbra offers a growth opportunity with roughly $1.4 billion in 2025 revenue, operating in complementary neurovascular and cardiovascular therapies.
  • Boston Scientific's diversified cardiovascular and MedSurg portfolio remains a counterweight to the weakness observed in its two pressured franchises.
Risk Factors
  • S&P Global Ratings revised the credit outlook to negative due to weaker-than-expected third-quarter results and a reduction in 2026 guidance.
  • Revenue growth is projected to slow to 4.4% in 2026 and 9% in 2027, well below the mid-to-high-teens rates achieved in 2024 and 2025.
  • The WATCHMAN franchise faces headwinds from clinical trial data uncertainty that increased physician hesitation and intensifying market competition.
  • The electrophysiology franchise is under pressure from strong competitors including Johnson & Johnson, Medtronic, and Abbott, weighing on market share recovery.
  • The $14.5 billion Penumbra acquisition will push adjusted leverage above 3.6 times at closing, significantly increasing financial risk compared to the 2.5-times downside trigger.
  • Elevated leverage is expected to remain high for two years following the deal as Boston Scientific integrates the acquired business and manages debt obligations.
Full Analysis
S&P Global Ratings has revised Boston Scientific's credit outlook to negative while affirming its A- issuer and senior unsecured debt ratings. This downgrade reflects increased pressure on key business segments, specifically the WATCHMAN left atrial appendage closure franchise and the electrophysiology division, which together account for a significant portion of the company's revenue. The agency cites weaker-than-expected third-quarter results and a subsequent reduction in 2026 guidance as primary drivers for this assessment. S&P forecasts revenue growth of 4.4% for 2026 and 9% for 2027, marking a notable slowdown from the mid-to-high-teens growth rates achieved in 2024 and 2025. The outlook highlights specific headwinds including clinical trial data uncertainty affecting physician confidence in WATCHMAN procedures and intensifying competition in the electrophysiology market. Furthermore, Boston Scientific's planned acquisition of Penumbra for $14.5 billion is expected to significantly increase leverage, pushing adjusted leverage ratios above 3.6 times at closing. This transaction adds substantial debt load that will remain elevated through 2028 as the company integrates the neurovascular and cardiovascular therapies portfolio. To restore a stable outlook, management must successfully execute cost-saving initiatives targeting $500 million in savings by 2029 while stabilizing market share in pressured franchises. Currently trading at 39.40 euros, Boston Scientific faces a critical path to lower leverage that depends on disciplined capital allocation and renewed operating growth. The company has announced plans to limit additional acquisitions and share repurchases during the integration period. A return to a stable credit rating will require mid-single-digit growth in other core franchises alongside improved performance from WATCHMAN and electrophysiology to offset the debt burden from the Penumbra deal.